Cargando…
Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension
Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963445/ https://www.ncbi.nlm.nih.gov/pubmed/36839767 http://dx.doi.org/10.3390/pharmaceutics15020446 |
_version_ | 1784896255718064128 |
---|---|
author | Cavelier, Marine Gondé, Henri Costa, Damien Lamoureux, Fabien Pereira, Tony Buchbinder, Nimrod Varin, Rémi Hervouët, Charles |
author_facet | Cavelier, Marine Gondé, Henri Costa, Damien Lamoureux, Fabien Pereira, Tony Buchbinder, Nimrod Varin, Rémi Hervouët, Charles |
author_sort | Cavelier, Marine |
collection | PubMed |
description | Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation. |
format | Online Article Text |
id | pubmed-9963445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99634452023-02-26 Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension Cavelier, Marine Gondé, Henri Costa, Damien Lamoureux, Fabien Pereira, Tony Buchbinder, Nimrod Varin, Rémi Hervouët, Charles Pharmaceutics Article Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation. MDPI 2023-01-29 /pmc/articles/PMC9963445/ /pubmed/36839767 http://dx.doi.org/10.3390/pharmaceutics15020446 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cavelier, Marine Gondé, Henri Costa, Damien Lamoureux, Fabien Pereira, Tony Buchbinder, Nimrod Varin, Rémi Hervouët, Charles Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title | Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title_full | Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title_fullStr | Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title_full_unstemmed | Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title_short | Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension |
title_sort | development of an oral liquid formulation of nicardipine hydrochloride compounded with simple excipients for the treatment of pediatric hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963445/ https://www.ncbi.nlm.nih.gov/pubmed/36839767 http://dx.doi.org/10.3390/pharmaceutics15020446 |
work_keys_str_mv | AT caveliermarine developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT gondehenri developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT costadamien developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT lamoureuxfabien developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT pereiratony developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT buchbindernimrod developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT varinremi developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension AT hervouetcharles developmentofanoralliquidformulationofnicardipinehydrochloridecompoundedwithsimpleexcipientsforthetreatmentofpediatrichypertension |